SAN

85.83

+0.01%↑

MRK1

115.45

-0.04%↓

ARGX

783.2

-1.01%↓

PHIA

24.23

-0.29%↓

ONC.US

339.45

-0.35%↓

SAN

85.83

+0.01%↑

MRK1

115.45

-0.04%↓

ARGX

783.2

-1.01%↓

PHIA

24.23

-0.29%↓

ONC.US

339.45

-0.35%↓

SAN

85.83

+0.01%↑

MRK1

115.45

-0.04%↓

ARGX

783.2

-1.01%↓

PHIA

24.23

-0.29%↓

ONC.US

339.45

-0.35%↓

SAN

85.83

+0.01%↑

MRK1

115.45

-0.04%↓

ARGX

783.2

-1.01%↓

PHIA

24.23

-0.29%↓

ONC.US

339.45

-0.35%↓

SAN

85.83

+0.01%↑

MRK1

115.45

-0.04%↓

ARGX

783.2

-1.01%↓

PHIA

24.23

-0.29%↓

ONC.US

339.45

-0.35%↓

Home・Aktien・Pharming Group NV

P
Pharming Group NV

Open

1.436 -1.24

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.426

Max

1.471

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.9M 7.5M
Verkäufe	4.1M 97M
EPS	0.009
Gewinnspanne	7.758
Angestellte	404

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	5.5M 1B
Vorheriger Eröffnungskurs	2.68
Vorheriger Schlusskurs	1.436

Pharming Group NV Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Nov. 2025, 16:49 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27. Nov. 2025, 15:32 UTC

Akquisitionen, Fusionen, Übernahmen

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27. Nov. 2025, 23:50 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27. Nov. 2025, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. Nov. 2025, 16:05 UTC

Market Talk

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27. Nov. 2025, 16:04 UTC

Market Talk

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27. Nov. 2025, 15:54 UTC

Akquisitionen, Fusionen, Übernahmen

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27. Nov. 2025, 15:44 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27. Nov. 2025, 15:43 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27. Nov. 2025, 15:42 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27. Nov. 2025, 15:41 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27. Nov. 2025, 15:11 UTC

Market Talk

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27. Nov. 2025, 14:26 UTC

Market Talk

Hermes' Outperformance Gap Could Narrow -- Market Talk

27. Nov. 2025, 14:11 UTC

Market Talk

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27. Nov. 2025, 14:11 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27. Nov. 2025, 13:35 UTC

Market Talk

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27. Nov. 2025, 13:33 UTC

Market Talk

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27. Nov. 2025, 13:22 UTC

Market Talk

Global Equities Roundup: Market Talk

27. Nov. 2025, 13:22 UTC

Market Talk

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27. Nov. 2025, 13:17 UTC

Market Talk

LVMH Should Be Able to Recover Next Year -- Market Talk

27. Nov. 2025, 11:13 UTC

Market Talk

European Gas Prices Come Under Pressure -- Market Talk

27. Nov. 2025, 11:07 UTC

Ergebnisse

Genting: Positive About Prospects Over Longer Term

27. Nov. 2025, 11:06 UTC

Ergebnisse

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27. Nov. 2025, 11:04 UTC

Ergebnisse

Genting: International Travel Demand Expected to Remain Resilient

27. Nov. 2025, 11:04 UTC

Ergebnisse

Genting: Global Growth Expected to Remain Subdued

27. Nov. 2025, 11:04 UTC

Ergebnisse

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27. Nov. 2025, 10:59 UTC

Ergebnisse

Genting Bhd 3Q Net Profit Fell 86% on Year

27. Nov. 2025, 10:58 UTC

Ergebnisse

Genting Bhd 3Q Rev Rose 14% on Year

27. Nov. 2025, 10:56 UTC

Ergebnisse

Genting Bhd 3Q Net MYR30.3M

27. Nov. 2025, 10:56 UTC

Ergebnisse

Genting Bhd 3Q EPS MYR0.0079

Peer-Vergleich

Kursveränderung

Pharming Group NV Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pharming Group NV – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.